GlaxoSmithKline Pharma Q2 net dips 25 per cent at Rs 96 crore
The company had posted a net profit of Rs 128.67 crore for the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a filing to BSE.
By PTI | Updated:
NEW DELHI: GlaxoSmithKline Pharmaceuticals today reported a 25.39 per cent dip in standalone net profit at Rs 96.05 crore for the quarter ended September 30.
The company had posted a net profit of Rs 128.67 crore for the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a filing to BSE.
Standalone total income from operations also declined to Rs 700.09 crore for the quarter under review as against Rs 746.76 crore for the corresponding period of previous fiscal.
Established in 1924 in India, GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines. The firm's prescription medicines range across therapeutic areas such as dermatology, anti-infectives, gynaecology, diabetes, cardiovascular diseases, respiratory diseases and oncology.
The company had posted a net profit of Rs 128.67 crore for the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a filing to BSE.
Standalone total income from operations also declined to Rs 700.09 crore for the quarter under review as against Rs 746.76 crore for the corresponding period of previous fiscal.
Established in 1924 in India, GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines. The firm's prescription medicines range across therapeutic areas such as dermatology, anti-infectives, gynaecology, diabetes, cardiovascular diseases, respiratory diseases and oncology.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Glaxosmithkline Pharma Q1 Results: Net profit rises 8% to Rs 116 croreADVERTISEMENT
